Free Trial

Dr. Martens (LON:DOCS) Reaches New 1-Year High - Here's Why

Dr. Martens logo with Consumer Cyclical background

Key Points

  • Dr. Martens' stock reached a new 52-week high, trading at GBX 84 ($1.13), signaling positive performance with over 1.5 million shares traded.
  • Equities analysts have adjusted their price targets, with Royal Bank of Canada lowering its target for Dr. Martens from GBX 7,000 ($94.56) to GBX 6,000 ($81.05).
  • The company reported a quarterly EPS of GBX 2.40 ($0.03) and forecasts earnings of 2.58 for the current fiscal year.
  • MarketBeat previews top five stocks to own in August.
  • Limited Time Offer: Unlock powerful research tools, advanced financial data, and expert insights to help you invest with confidence. Save 50% when you upgrade to MarketBeat All Access during the month of July. Claim your discount here.

Dr. Martens plc (LON:DOCS - Get Free Report)'s stock price hit a new 52-week high on Friday . The stock traded as high as GBX 84 ($1.13) and last traded at GBX 83.86 ($1.13), with a volume of 1542027 shares traded. The stock had previously closed at GBX 82.60 ($1.12).

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on DOCS shares. Royal Bank Of Canada cut their price target on shares of Dr. Martens from GBX 7,000 ($94.56) to GBX 6,000 ($81.05) and set a "sector perform" rating on the stock in a report on Monday, May 19th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Dr. Martens in a report on Friday, July 11th.

View Our Latest Stock Analysis on Dr. Martens

Dr. Martens Trading Up 2.1%

The company has a current ratio of 2.85, a quick ratio of 1.13 and a debt-to-equity ratio of 127.27. The company has a 50-day simple moving average of GBX 71.64 and a 200 day simple moving average of GBX 64.41. The firm has a market cap of £818.35 million, a PE ratio of 11.95, a price-to-earnings-growth ratio of 6.40 and a beta of 0.11.

Dr. Martens (LON:DOCS - Get Free Report) last released its quarterly earnings data on Thursday, June 5th. The company reported GBX 2.40 ($0.03) EPS for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. As a group, sell-side analysts forecast that Dr. Martens plc will post 2.5809394 earnings per share for the current fiscal year.

Dr. Martens Company Profile

(Get Free Report)

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Dr. Martens Right Now?

Before you consider Dr. Martens, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Martens wasn't on the list.

While Dr. Martens currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines